Investigation of the Structure-Activity Relationships of Psilocybin Analogues
This cell and mice study investigated 17 psilocybin analogs and found similar activation patterns of the 5-HT2 receptors. The mouse studies also found similar behavioral (head-twitch) responses. Some analogs did show different activation patterns than expected.
Authors
- John McCorvy
- Adam Halberstadt
- Simon Brandt
Published
Abstract
The 5-HT2A receptor is thought to be the primary target for psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) and other serotonergic hallucinogens (psychedelic drugs). Although a large amount of experimental work has been conducted to characterize the pharmacology of psilocybin and its dephosphorylated metabolite psilocin (4-hydroxy-N,N-dimethyltryptamine), there has been little systematic investigation of the structure-activity relationships (SAR) of 4-substituted tryptamine derivatives. In addition, structural analogs of psilocybin containing a 4-acetoxy group, such as 4-acetoxy-N,N-dimethyltryptamine (4-AcO-DMT), have appeared as new designer drugs, but almost nothing is known about their pharmacological effects. To address the gap of information, SAR studies were conducted with 17 tryptamines containing a variety of symmetrical and asymmetrical N,N-dialkyl substituents and either a 4-hydroxy or 4-acetoxy group. Calcium mobilization assays were conducted to assess functional activity at human and mouse 5-HT2 subtypes. Head-twitch response (HTR) studies were conducted in C57BL/6J mice to assess 5-HT2A activation in vivo. All of the compounds acted as full or partial agonists at 5-HT2 subtypes, displaying similar potencies at 5-HT2A and 5-HT2B receptors, but some tryptamines with bulkier N-alkyl groups had lower potency at 5-HT2C receptors and higher 5-HT2B receptor efficacy. In addition, O-acetylation reduced the in vitro 5-HT2A potency of 4-hydroxy-N,N-dialkyltryptamines by about 10-20-fold but did not alter agonist efficacy. All of the compounds induce head twitches in mice, consistent with an LSD-like behavioral profile. In contrast to the functional data, acetylation of the 4-hydroxy group had little effect on HTR potency, suggesting that O-acetylated tryptamines may be deacetylated in vivo, acting as pro-drugs. In summary, the tryptamine derivatives have psilocybin-like pharmacological properties, supporting their classification as psychedelic drugs.
Research Summary of 'Investigation of the Structure-Activity Relationships of Psilocybin Analogues'
Introduction
Klein and colleagues situate this work within renewed scientific and public interest in psilocybin and related 4-substituted tryptamines. The introduction notes that psilocybin is rapidly dephosphorylated to psilocin and that psilocin is widely accepted as the active species at serotonergic targets, especially the 5-HT2A receptor, which is implicated in the psychedelic effects of LSD, mescaline and related compounds. Although many 4-hydroxy and 4-acetoxy tryptamines have been described historically and more recently have appeared as recreational designer drugs, the authors identify a gap in systematic structure-activity relationship (SAR) data for N,N-dialkyl substitutions and for O-acetylated analogues such as 4-AcO-DMT. To address this gap, the investigators examined a panel of 16 4-substituted N,N-dialkyltryptamines containing either a 4-hydroxy or 4-acetoxy group. Their primary aims were to characterise functional agonism at human and mouse 5-HT2 receptor subtypes in vitro using calcium mobilization assays, and to assess 5-HT2A-mediated behavioural activity in vivo using the mouse head-twitch response (HTR). The combined in vitro and in vivo approach was intended both to map how N-alkyl substitution affects receptor activity and to evaluate whether the O-acetylated compounds behave as prodrugs of the corresponding 4-hydroxy tryptamines.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Create a free account to open full-text PDFs.
Study Details
- Study Typeindividual
- Journal
- Compound
- Topic
- Authors
- APA Citation
Klein, A. K., Chatha, M., Laskowski, L. J., Anderson, E. I., Brandt, S. D., Chapman, S. J., McCorvy, J. D., & Halberstadt, A. L. (2021). Investigation of the Structure-Activity Relationships of Psilocybin Analogues. ACS Pharmacology & Translational Science, 4(2), 533-542. https://doi.org/10.1021/acsptsci.0c00176
References (18)
Papers cited by this study that are also in Blossom
Leonard, J. B., Klein-Schwartz, W. · Journal of Psychopharmacology (2018)
Kjellgren, A., Soussan, C. · Journal of Psychoactive Drugs (2011)
Palamar, J. J., Acosta, P. · Human Psychopharmacology (2020)
Tittarelli, R., Mannocchi, G., Pantano, F. et al. · Current Neuropharmacology (2015)
Blough, B. E., Landavazo, A., Decker, A. M. et al. · Psychopharmacology (2014)
Halberstadt, A. L. · Behavioural Brain Research (2014)
Nichols, D. E. · Pharmacological Reviews (2016)
Gonza ´lez-Maeso, J., Weisstaub, N. V., Zhou, M. et al. · Neuron (2007)
Halberstadt, A. L., Chatha, M., Klein, A. K. et al. · Neuropharmacology (2020)
Anderson, T., Petranker, R., Rosenbaum, D. et al. · Psychopharmacology (2019)
Show all 18 referencesShow fewer
Rickli, A., Moning, O. D., Hoener, M. C. et al. · European Neuropsychopharmacology (2016)
Hutten, N. P. W., Mason, N. L., Dolder, P. C. et al. · International Journal of Neuropsychopharmacology (2019)
Polito, V., Stevenson, R. J. · PLOS ONE (2019)
Holze, F., Vizeli, P., Ley, L. et al. · Neuropsychopharmacology (2020)
Kraehenmann, R. ;., Pokorny, D. ;., Vollenweider, L. ;. et al. · Psychopharmacology (2017)
Preller, K. H., Herdener, M., Pokorny, T. et al. · Current Biology (2017)
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A. et al. · NeuroReport (1998)
Madsen, M. K., Fisher, P. M., Burmester, D. et al. · Neuropsychopharmacology (2019)
Cited By (10)
Papers in Blossom that reference this study
Puigseslloses, P., Nadal-Gratacós, N., Ketsela, G. et al. · Molecular Psychiatry (2024)
Rouaud, A., Calder, A. E., Hasler, G. · Journal of Psychopharmacology (2024)
Ekins, T. G., Brooks, I., Kailasa, S. et al. · Biorxiv (2023)
Tagen, M., Mantuani, D., Van Heerden, L. et al. · Journal of Psychopharmacology (2023)
Wallach, J., Cao, A. B., Calkins, M. M. et al. · Biorxiv (2023)
Lewis, V., Bonniwell, E. M., Lanham, J. K. et al. · Cell Reports (2023)
Cunningham, M. J., Bock, H. A., Serrano, I. C. et al. · ACS Chemical Neuroscience (2022)
Kwan, A. C., Olson, D. E., Preller, K. H. et al. · Nature Medicine (2022)
Hesselgrave, N., Troppoli, T. A., Wulff, A. B. et al. · PNAS (2021)
Olson, D. E. · ACS Pharmacology and Translational Science (2021)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.